Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $553,200.00 in Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $27.66, for a total transaction of $553,200.00. Following the transaction, the director now directly owns 3,462,584 shares in the company, valued at approximately $95,775,073.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Simulations Plus Stock Down 0.4 %

Shares of NASDAQ SLP opened at $30.70 on Friday. The business’s 50 day moving average is $31.71 and its two-hundred day moving average is $39.54. Simulations Plus, Inc. has a 52-week low of $27.22 and a 52-week high of $51.22. The firm has a market cap of $616.15 million, a price-to-earnings ratio of 62.65 and a beta of 0.71.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The business had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same period in the previous year, the firm posted $0.18 earnings per share. The company’s revenue was up 19.9% on a year-over-year basis. Analysts anticipate that Simulations Plus, Inc. will post 1.11 EPS for the current fiscal year.

Institutional Trading of Simulations Plus

Institutional investors and hedge funds have recently bought and sold shares of the business. Tributary Capital Management LLC grew its stake in shares of Simulations Plus by 54.7% in the third quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock worth $10,425,000 after acquiring an additional 115,122 shares in the last quarter. Silvercrest Asset Management Group LLC purchased a new position in Simulations Plus in the first quarter valued at $4,717,000. Royce & Associates LP grew its stake in Simulations Plus by 28.8% during the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock worth $7,602,000 after purchasing an additional 53,092 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Simulations Plus by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after purchasing an additional 37,992 shares in the last quarter. Finally, Congress Asset Management Co. boosted its stake in shares of Simulations Plus by 22.5% in the 3rd quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock valued at $6,613,000 after buying an additional 37,914 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday. BTIG Research lowered their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. KeyCorp began coverage on Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price on the stock. Finally, JMP Securities initiated coverage on Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.